MICALL2

Across TCGA pan-cancer cohorts, MICALL2 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated MICALL2 data layer compared with 4 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MICALL2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MICALL2 expression acts as an unfavorable survival marker, although some lineages such as DLBC and SKCM show a favorable association.

KIRC, MESO, and UVM are the cancer types where MICALL2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.548	0.699	<.001	155	view →
MESO	OS	Quartile	All	0.232	0.558	<.001	80	view →
UVM	DFS	Median	All	0.330	0.607	.001	77	view →
ACC	DFS	Median	All	0.259	0.672	<.001	54	view →
LGG	DFS	Median	All	0.272	0.480	<.001	53	view →
LIHC	OS	Quartile	All	0.456	0.639	.002	48	view →
OV	OS	Tertile	III,IV	0.272	0.355	.017	26	view →
UCS	OS	Tertile	III,IV	0.295	0.622	.030	24	view →
COAD	OS	Quartile	II,III,IV	0.707	0.897	.001	24	view →
PRAD	DFS	Median	All	0.692	0.885	<.001	24	view →
DLBC	DFS	Tertile	All	1.000	0.151	.004	20	view →
SKCM	OS	Tertile	IV	0.955	0.530	.016	19	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

MICALL2–KIRC (DFS)

Open the KIRC breakdown →